The short answer
The added bleeding risk from Ginkgo biloba with ticagrelor is uncertain. Review the exact product, dose and your bleeding history with your prescriber.
What this answer covers
Oral Ginkgo biloba with oral ticagrelor tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable.
- Supplement or preparation
- Ginkgo biloba
- Medication ingredient
- ticagrelor
What the evidence shows
A short study in healthy men found no additional measured bleeding-time or platelet effect when a defined ginkgo extract was added to aspirin. This is useful counterevidence, but it did not test this antiplatelet medicine or patients with a history of GI bleeding.
Consider the prescribed treatment
Ticagrelor reduces platelet activity and can cause serious bleeding. The label also warns that stopping it increases cardiovascular risk, including stent-related harm in relevant patients. Have your prescribing team review supplements and procedure plans; do not stop ticagrelor or assume that a few hours of spacing removes a possible bleeding concern.
Review the exact product
The final European ginkgo monograph cautions about use with medicines affecting clotting, including other antiplatelet medicines. Review the exact leaf extract and dose with your pharmacist. This precaution does not establish a measured increase in bleeding for every ginkgo product.
Know when to get help
Seek urgent care for bleeding that will not stop, vomiting blood or black, tarry stools. Tell your prescriber about the full supplement and medicine list. Do not stop prescribed antiplatelet treatment on your own to accommodate a supplement; ask the treating team to make a plan.
Evidence and practical considerations
Side effects & toxicity
An increased bleeding rate specifically from Ginkgo biloba with ticagrelor has not been established.
- Exact scope
- Oral Ginkgo biloba with oral ticagrelor tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable. with Exact ticagrelor RxCUI1116632 IN. Oral parent drug and active metabolite have antiplatelet activity; other P2Y12 drugs are not interchangeable.
- Medication form and route
- Oral
What remains uncertain
- Available supplement-only and other-drug studies do not establish exact-pair clinical harm or exclude rare events. No validated preventive spacing interval.
Factors that may matter: Exact preparation and dose; Fasting versus fed dosing; Bleeding and ulcer history; Other medicines.
Read the supporting source summaries
Source 1: Current prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Prescription oral oral ticagrelor tablets users; short human pharmacology studies where described.
Significant bleeding risk; stopping treatment raises cardiovascular risk. Strong CYP3A inducers lower exposure and efficacy and should be avoided.
How this applies: Exact current product label. Exact ticagrelor RxCUI1116632 IN. Oral parent drug and active metabolite have antiplatelet activity; other P2Y12 drugs are not interchangeable.
No exact botanical bleeding rate. Rifampin exposure changes are not an effect size for St. John’s wort.
Source 2: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 50 healthy men aged 20-44.
No added measured bleeding-time or platelet/coagulation effect.
How this applies: Indirect for oral ticagrelor tablets co-use; exact preparation and endpoint retained.
Abstract-only; aspirin is a different medicine and the short study does not exclude rare bleeding.
Source 3: Medication terminology
rxnav.nlm.nih.gov · Source check Sep 10, 2026
Population: Terminology.
ticagrelor is IN.
How this applies: Exact identity.
Not clinical evidence.
Research assessment: · Open full citations ↗
Side effects & toxicity
Defined ginkgo preparations warrant review with antiplatelet medicines under regulatory guidance.
- Exact scope
- Oral Ginkgo biloba with oral ticagrelor tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable. with Exact ticagrelor RxCUI1116632 IN. Oral parent drug and active metabolite have antiplatelet activity; other P2Y12 drugs are not interchangeable.
- Medication form and route
- Oral
What remains uncertain
- Precaution based on defined supplement evidence and the individual drug label; no exact combination event rate or universal discontinuation rule.
Factors that may matter: Exact preparation and dose; Fasting versus fed dosing; Bleeding and ulcer history; Other medicines.
Read the supporting source summaries
Source 1: Current prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Prescription oral oral ticagrelor tablets users; short human pharmacology studies where described.
Significant bleeding risk; stopping treatment raises cardiovascular risk. Strong CYP3A inducers lower exposure and efficacy and should be avoided.
How this applies: Exact current product label. Exact ticagrelor RxCUI1116632 IN. Oral parent drug and active metabolite have antiplatelet activity; other P2Y12 drugs are not interchangeable.
No exact botanical bleeding rate. Rifampin exposure changes are not an effect size for St. John’s wort.
Source 2: Final regulatory herbal monograph
ema.europa.eu · Source check Sep 10, 2026
Population: Users of specified ginkgo leaf preparations.
Cautions that anticoagulant/antiplatelet effects, including those of other NSAIDs, may be influenced.
How this applies: NSAID class precaution with individual drug counterevidence retained.
Regulatory precaution, not exact oral ticagrelor tablets trial. Different extracts and populations may differ.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Sources checked and article drafted. | |
| Research summary published |
Article revision: d97e9b95120da34b
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.